Photo taken from Meredith McKean/LinkedIn
Jun 25, 2024, 04:14
Dr. Meredith McKean’s recent discussion on PD-1–refractory advanced melanoma at ecancer – Sarah Cannon Research Institute
Sarah Cannon Research Institute shared on LinkedIn:
“Dr. Meredith McKean‘s recent discussion on PD-1–refractory advanced melanoma at ecancer underscores our commitment to navigating through the toughest challenges in cancer treatment. Her insights are showing how this research is paving the way to new therapeutic strategies.”.
Read further.
Source: Sarah Cannon Research Institute/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 22, 2025, 05:18
Feb 22, 2025, 05:15
Feb 22, 2025, 05:05
Feb 22, 2025, 04:54
Feb 22, 2025, 04:49
Feb 22, 2025, 04:33
Feb 22, 2025, 04:29